To,

All the Chief Medical Officers,
Himachal Pradesh

Dated Shimla-9 the

Subject: Recommendations of State COVID Clinical Team

Sir/Madam,

The State COVID Clinical Team has made the following recommendations that needs to be taken into pursuance

1. Active tracking and intensive IEC activities targeting vulnerable and co-morbid group be done in order to prevent delay in seeking early and proper medical care.

2. COVID-19 positive patients with co-morbidities even if mild should be hospitalized as they are prone to rapid deterioration.

3. Suspected patient with pending COVID report particularly patient with co-morbidities and if there are clinical indications, should be hospitalized.

4. Use of Remdesivir in COVID-19 patients with renal insufficiency have the potential issues regarding toxicities hence its use should be monitored as per Annexure 1.

In this regard you are requested to take necessary steps at the earliest.

Mission Director
National Health Mission
Himachal Pradesh

Dated Shimla-9 the

Copy to:

1. The Secretary (Health) to the Government of Himachal Pradesh

2. All the Deputy Commissioners, Himachal Pradesh.
3. Director Health Services, Himachal Pradesh. The State Level COVID Clinical Team has also suggested that the deputation of staff including Specialized Physicians, Pediatricians, Anesthetist, Medical Officers and Nursing staff on the rotation basis from the peripheral institutes to IGMC Shimla, Dr. RPGMC at Tanda and Dr. SLBSGMC, Ner Chowk, Mandi be done, so that management of COVID-19 positive patient may be carried out effectively. You are requested to take further necessary action in the matter.

4. Director Medical Education & Research, Himachal Pradesh. The State Level COVID Clinical Team has also suggested the facility of CT Scan be provided at SLBSGMC Nerchowk, Mandi for monitoring of COVID-19 positive patients.

5. All the Medical Superintendents, Himachal Pradesh.

6. All Nodal Officers, CCC/DCHC/DCH in Himachal Pradesh.

7. All the District Surveillance Officers in Himachal Pradesh.

8. State COVID Clinical Team.

9. COVID Clinical Committees of all the Medical Colleges of Himachal Pradesh.

Annexure-1

Use of Remdesivir in COVID-19 patients with renal insufficiency has 2 potential issues regarding toxicities:

a. Direct nephrotoxicity: has much less mitochondrial toxicity and should be safe in short courses given in disease

b. Cyclodextrin (SBEC) is the vehicle for Remdesivir. Each 100 mg of Remdesivir contains 6gm of SBEC, well below the maximum safety threshold 250 mg/kg per day of SBEC & is removed by dialysis. So is relatively safe at lower doses. Though, Remdesivir is not recommended, however, it can be given with a risk-benefit assessment. Therefore, we may administer Remdesivir in these patients after proper risk-benefit assessment. If the patient is on continuous renal replacement therapy or is expected to begin it, the risk of cyclodextrin accumulation is low. Patients at highest risk of cyclodextrin accumulation are those who have pre-existing advanced chronic kidney disease and no plan for dialysis.